Sangamo Therapeutics’ (SGMO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Jefferies Financial Group dropped their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Wells Fargo & Company dropped their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Barclays raised their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, December 13th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Sangamo Therapeutics Trading Up 15.0 %

Sangamo Therapeutics stock opened at $1.30 on Thursday. The firm has a market cap of $271.24 million, a price-to-earnings ratio of -1.73 and a beta of 1.15. The stock has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $1.24. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter last year, the company earned ($0.34) EPS. On average, equities research analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SGMO. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics during the second quarter valued at $67,000. Meritage Portfolio Management lifted its position in Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Sangamo Therapeutics during the second quarter valued at $89,000. XTX Topco Ltd lifted its position in Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares in the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.